All News

Lupusfoto.jpg

Progress in SLE with new mRNA CAR-T cell Trial

d Jack Cush, MD

Cartesian Therapeutics, has announced their first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) therapy has been given to the first systematic lupus erythematosus (SLE). patient in a Phase 2 open-label clinical trial. 

Read Article
kidneys

Efficacy of Biologics in Patients with Chronic KIdney Disease

d Jack Cush, MD

A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis (RA) patients with chronic kidney disease (CKD), shows the 3 year survicval to be under 50% but that all studied biologics were nearly equivalent

Read Article
PMR spotlight

PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis?

d Jack Cush, MD

Despite the clinical similarities and treatment differences between  giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders.

Read Article
cost.healthcare.jpg

Cost-Effectiveness of Biosimilars vs Leflunomide

d Jack Cush, MD

An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) were cost-effective compared with the conventional DMARD, leflunomide.

Read Article
Paradoxical psoriasis w/ IL-17 inhib? Lit review 35 (SpA) pts, presenting as palmoplantar pustular and plaque PsO; median 11 weeks after IL-17i. one-third continued IL-17i w/ mostly topical Rx; 2/3 D/C IL-17i, switching to other biologic w/ good outcomes https://t.co/q2xqQyiM3b https://t.co/6hSE6NLHWw

Links:

Dr. John Cush RheumNow ( View Tweet)
5 yr results of 150 difficult-to-treat RA pts - D2T RA resolved in 45%, persisted in 50%, & 5% died. Resolved D2T RA was signif younger, had more Rx changes, & more IL-6i use. Mortality predicted by comorbidity index, steroid escalation (OR 3.50; & 32) https://t.co/cIUNcQ0r3F https://t.co/rNZaWu3Ocd

Links:

Dr. John Cush RheumNow ( View Tweet)
In early arthritis (RA) pts there is no value in measuring for IgA-ACPA or IgA-RF, as there presence doesnt provide more than IgG-ACPA. In tREACH trial IgA-ACPA present in 23% & overlaped w/ IgG-ACPA in 94% (w/ IgM-RF in 90%). https://t.co/d8Xc4GBfEt https://t.co/qvujVx0RFf

Links:

Dr. John Cush RheumNow ( View Tweet)
CT angio in 75 pts w/ Takayasu arteritis (40 w/ cDMARDs, 35 biologics) showed reduced arterial thickness in 73% (31% w/ >25% decr in wall thickness). 1st immunosuppressives (p= 0.012) & bDMARDs(p= 0.026) reduced art. wall thickness (relative to cDMARDs) https://t.co/16eGmgVoWr https://t.co/AyNyT7FsYZ

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA adverse event study of JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JAKi vs 303,278 on biologics (TNFi, RTX, TCZ); JAK had more VTE (ROR=2.11), CVA (ROR=1.25), IHD (1.23), arrhythmias (1.15 ), esp in 1st yr. https://t.co/BmNPk6zN6o https://t.co/fbzHQmPmH5

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Topic Panel: EULAR 2024 Dr. Jack Cush moderates this topic panel with Drs. Eric Ruderman, Peter Nash and Antoni Chan. https://t.co/XUFgUUqBu2 https://t.co/08TPtQWBvx

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 Recommendations on Reproductive Health https://t.co/QuXQlpQv8O https://t.co/nHC7LOLLl8

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations https://t.co/abcs8RwJ5J https://t.co/wLOq4bK7qQ

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Best Imaging in Giant Cell Arteritis - US, PET, MRI? https://t.co/J4aE4jxNb0 https://t.co/b6axwp4Tuw

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update https://t.co/iccSFuAogX https://t.co/ORzwvDKqVo

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes https://t.co/46g8ek286u https://t.co/FEFq4vkiPk

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: 9 Facts about Leflunomide Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. https://t.co/WseVa589Fg. https://t.co/K4u00MbwEb

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: JAMA: SLE Review https://t.co/GJJSOYZru2 https://t.co/mCgWy27yPr

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: BSR Guideline on Management of Sjogren’s Syndrome https://t.co/MMG3NmCeDl https://t.co/zKlR8jOkLD

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of Amyloidosis The New England Journal of Medicine has published a review of systemic amyloidosis. https://t.co/qtbdPrlKnj https://t.co/wcqvRAauWC

Links:

Dr. John Cush RheumNow ( View Tweet)
Predicting Palindromic Prognosis Dr. David Liew discusses abstract OP0127, "PREDICTING PERSISTENT INFLAMMATORY ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM: DEVELOPMENT OF SCORES FOR RISK STRATIFICATION", at Eular 2024 in Vienna, Austria. https://t.co/Yzr9feNjjF https://t.co/BKVbDv3e4E

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×